pre-NOC
On September 5th, 2024, Katherine Scott and Lana Duan from MORSE Consulting presented “Accelerating Access: Leveraging Target Zero to Expedite Time to Access for New Therapies” at the CDA-AMC Symposium. They explored how pre-NOC submissions impact market access timelines, using CDA-validated data and insights from our internal database.Download our presentation to learn more about these findings and strategies for accelerating access to new therapies. Panelists We'd like to thank all…
INESSS Introduces New Pre-NOC and Biosimilar Guidance The Institut national d'excellence en santé et en services sociaux (INESSS) released its new submission guidelines on June 2nd, 2017. The guidelines, which are now effective, include revised and new Form applications and letter templates for drug submissions. The two major highlights relate to pre-NOC review and the introduction of new guidelines for biosimilar submissions. Pre-NOC Review Unlike the CADTH pre-NOC guidelines…
Contact Us
MORSE Consulting Inc.
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. |
Site by Directica Media
pre-NOC | MORSE Consulting Inc.
